Annual report pursuant to Section 13 and 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.22.1
Revenues from Contracts and Significant Customers (Tables)
12 Months Ended
Dec. 31, 2021
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

The table below summarizes the Company’s revenue for the years ended December 31, 2021 and 2020:

Year Ended December 31, 

    

2021

    

2020

Revenue

Targadox®

$

22,378

$

30,708

Ximino®

8,247

9,518

Exelderm®

5,363

4,453

Accutane®

10,053

Qbrexza®

17,056

Other branded revenue

37

(148)

Collaboration revenue

5,389

Revenue – related party

 

268

 

1,068

Net revenue

$

68,791

$

45,599